Dr Chris Painter

Email More

Health Economist

Mahidol-Oxford Tropical Medicine Research Unit

Chris Painter is a health economist at the Mahidol-Oxford Tropical Medicine Research Unit, based in Bangkok, Thailand. Chris is interested in health technology assessment and using economic evaluations to inform policy decisions for resource allocation decisions and priority setting. Chris has experience conducting a range of health economic analyses for both non-communicable and communicable diseases, including cost-effectiveness, budget impact and cost-of-illness analyses, using Markov, decision trees and dynamic transmission modelling techniques.

Related Projects

Related publications

• Wang, Y., Luangasanatip, N., Pan–ngum, W., Isaranuwatchai, W., Prawjaeng, J., Saralamba, S., Painter, C., Briones, J.R. and Teerawattananon, Y., 2023. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: The case of Thailand at start of the pandemic. The European Journal of Health Economics, 24(5), pp.735-748.
• Kingkaew, P., Budtarad, N., Khuntha, S., Barlow, E., Morton, A., Isaranuwatchai, W., Teerawattananon, Y. and Painter, C., 2022. A model-based study to estimate the health and economic impact of health technology assessment in Thailand. International Journal of Technology Assessment in Health Care, 38(1) p.e45.
• Painter, C., Isaranuwatchai, W., Prawjaeng, J., Wee, H.L., Chua, B.W.B., Huynh, V.A., Lou, J., Goh, F.T., Luangasanatip, N., Pan-Ngum, W. and Yi, W., 2021. Avoiding trouble ahead: lessons learned and suggestions for economic evaluations of COVID-19 vaccines. Applied Health Economics and Health Policy, 19(4), pp.463-472.
• Girardin, F., Painter, C., Hearmon, N., Eddowes, L., Kaiser, S., Negro, F. and Vernaz, N., 2021. Hepatitis C prevalences in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. JHEP Reports, 3(3), p.100279.